MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2

Meng Xu1, Dongmei Zuo1, Xingxing Liu1

  • 1Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Insights

MicroRNA-155 (miR-155) exacerbates inflammatory bowel disease by promoting Th17 cell differentiation. Inhibiting miR-155 in dextran sulfate sodium-induced colitis models reduced colonic damage and Th17 cell frequency.

Area of Science:

  • Immunology
  • Molecular Biology
  • Gastroenterology

Background:

  • MicroRNAs (miRNAs) regulate immune responses via mRNA destabilization or translational inhibition.
  • Elevated miR-155 levels are observed in active ulcerative colitis (UC) colonic tissues.
  • The specific role of miR-155 in UC pathogenesis and its influence on immune responses in dextran sulfate sodium (DSS)-induced colitis remain unclear.

Purpose of the Study:

  • To investigate the role of miR-155 in the pathogenesis of UC.
  • To elucidate the mechanism by which miR-155 influences immune responses in DSS-induced colitis.
  • To identify direct targets of miR-155 relevant to UC.

Main Methods:

  • Bioinformatics analysis and luciferase reporter assays to identify miR-155 targets.
  • In situ hybridization, immunofluorescence, and flow cytometry to assess molecular and cellular changes in DSS-induced colitis mice.
  • Lentiviral vectors used to deliver miR-155 inhibition sequences for gene silencing in epithelial cells.

Main Results:

  • Jarid2 was identified as a direct target of miR-155.
  • DSS-induced colitis mice showed increased miR-155 and Th17 cell frequency, alongside decreased Jarid2 levels.
  • Inhibition of miR-155 attenuated DSS-induced colonic damage and suppressed Th17 cell differentiation.

Conclusions:

  • miR-155 plays a detrimental role in DSS-induced colitis.
  • miR-155 promotes Th17 cell differentiation by targeting Jarid2.
  • Targeting miR-155 may represent a therapeutic strategy for UC.